Persons who are 6 months to 4 years should complete the primary series of vaccination with:
Two doses of Moderna/Spikevax, given eight weeks apart, OR
Three doses of Pfizer-BioNTech/Comirnaty, given eight weeks apart.
Persons who are aged 5 and above should adhere to the following vaccination recommendation:
Persons aged 5 years and above should receive minimum protection (see footnote on age eligibility). That is, to receive:
Three doses of Pfizer-BioNTech/Comirnaty*, Moderna/Spikevax or Novavax/Nuvaxovid^. The first and second doses should be spaced eight weeks apart, while the recommended interval between the second and third doses is five months; OR,
Four doses of Sinovac-CoronaVac. The first and second doses should be spaced eight weeks apart. Thereafter, the recommended interval between the second and third, as well as third and fourth doses is three months.
These would be doses that were previously referred to as the primary vaccination series and the first additional dose.
* Children aged 6 months to 4 years who had previously received three doses of Pfizer-BioNTech/Comirnaty should still receive an additional dose after they have crossed their fifth birthday, if they have not done so. The interval between the additional dose and the last dose should be 5 months or more.
Additional Vaccination Dose in 2023/ 2024
An additional dose of the updated vaccine at 1 year after the last dose is recommended in the following persons. They can start to receive it from five months after their last dose.
· All persons aged 60 years and above;
· Medically vulnerable persons; and
· Residents of aged care facilities
An additional dose of the updated vaccine is encouraged for Individuals aged 6 months and above, in particular, healthcare workers, as well as household members and caregivers of medically vulnerable individuals.
The Pfizer-BioNTech/Comirnaty and Moderna/Spikevax vaccines are recommended for this. Those who are medically ineligible for mRNA vaccines may receive Novavax/Nuvaxovid^ or Sinovac-CoronaVac as an alternative.
Note: Sinovac-CoronaVac vaccine continues to be included under the NVP. However, if there is no application for Sinovac-CoronaVac vaccine to be fully registered, NVP will lapse for Sinovac-CoronaVac vaccine, by 30 September 2024. Nevertheless, Sinovac-CoronaVac vaccine will continue to be available at private clinics which have applied to use it under the Special Access Route (SAR). Under the NVP, vaccination is free for all Singaporean Citizens, Permanent Resident, Long Term Pass Holders and certain Short Term Pass holders. However, age eligibility for the various vaccines apply. Under the National Vaccination Programme, persons aged 6 months to 17 years are eligible to receive the Pfizer-BioNTech/Comirnaty and Moderna/Spikevax vaccine. Persons aged 18 years and older are eligible to receive the Pfizer-BioNTech/Comirnaty, Moderna/Spikevax, Novavax/Nuvaxovid^ or Sinovac-CoronaVac vaccines.
^The Novavax/Nuvaxovid vaccine is currently unavailable under the NVP. Novavax is in the process of filing for regulatory approval for its updated COVID-19 XBB.1.5 vaccine formulation.